2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-151236
    Antitubercular agent-30 384857-54-9 99.90%
    Antitubercular agent-30 is an antibacterial agent against Mycobacterium tuberculosis (MIC=50 μg/mL). Antitubercular agent-30 has little cytotoxic effect on murine macrophage cells (LD85=~100 μg/mL).
    Antitubercular agent-30
  • HY-151250
    HIV-1 protease-IN-7 2916441-36-4 98%
    HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC50=3.52 nM, EC50=37 nM).
    HIV-1 protease-IN-7
  • HY-151251
    CYP2C9/CYP2C19-IN-1 3010895-55-0 98%
    CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent CYP2C9/CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV.
    CYP2C9/CYP2C19-IN-1
  • HY-151253
    CYP2C1/CYP2C19-IN-2 3010895-54-9 98%
    CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent CYP2C9/CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV.
    CYP2C1/CYP2C19-IN-2
  • HY-151254
    CYP2C19-IN-1 3010895-53-8 98%
    CYP2C19-IN-1 (compound 20d) is a potent CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a Ki value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV.
    CYP2C19-IN-1
  • HY-151265
    MMT5-14 2719679-31-7 98%
    MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19.
    MMT5-14
  • HY-151267
    SARS-CoV-2-IN-25 98%
    SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes.
    SARS-CoV-2-IN-25
  • HY-151269
    SARS-CoV-2-IN-26 98%
    SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
    SARS-CoV-2-IN-26
  • HY-151271
    SARS-CoV-2-IN-27 98%
    SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC50 value of 6.5 μM.
    SARS-CoV-2-IN-27
  • HY-151274
    SARS-CoV-2-IN-28 98%
    SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
    SARS-CoV-2-IN-28
  • HY-151276
    SARS-CoV-2-IN-29 98%
    SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC50 value of 3.0 μM.
    SARS-CoV-2-IN-29
  • HY-151278
    SARS-CoV-2-IN-30 98%
    SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC50 value of 6.9 μM.
    SARS-CoV-2-IN-30
  • HY-151280
    Antifungal agent 37 2833772-92-0 98%
    Antifungal agent 37 is a geterocyclic disulfide, with antifungal activity.
    Antifungal agent 37
  • HY-151339
    Antitubercular agent-31 2764818-29-1 98%
    Antitubercular agent-31 (Compound 2) is an antitubercular agent with an MIC of 0.03 μM against M. tuberculosis H37Rv. Antitubercular agent-31 also inhibits DprE1 with an IC50 of 1.1 μM.
    Antitubercular agent-31
  • HY-151340
    Antitubercular agent-32 2498762-42-6 98%
    Antitubercular agent-32 is a derivate of Benzothiazinone (HY-13579A), inhibits M. tuberculosis, and shows improved metabolic stability and enhanced water solubility. Antitubercular agent-32 exerts antitubercular effect by targeting decaprenylphosphoryl-β-D-ribose 2’-oxidase (DprE1, IC50=3.9 μM).
    Antitubercular agent-32
  • HY-151352
    DHDPS-IN-1 1233344-34-7 98%
    DHDPS-IN-1 (compound 8) is a DHDPS inhibitor (IC50: 39 μM). DHDPS-IN-1 can be used in the area of antibacterial and herbicidal.
    DHDPS-IN-1
  • HY-151354
    Antibacterial agent 121 474099-18-8 98%
    Antibacterial agent 121 (Compound 10) is an antibacterial agent. Antibacterial agent 121 shows anti-mycobacterial and anti-inflammatory activities and can be used in Tuberculosis (TB) research.
    Antibacterial agent 121
  • HY-151356
    Antibacterial agent 122 109310-99-8 98%
    Antibacterial agent 122 (compound 15) is a thiourea derivative with anti-mycobacterial activity and low cytotoxicity. Antibacterial agent 122 can be used for tuberculosis-related studies.
    Antibacterial agent 122
  • HY-151357
    MraY-IN-3 2851534-52-4 98%
    MraY-IN-3 (12a) is a potent bacterial translocase MraY inhibitor with an IC50 value of 140 µM. MraY-IN-3 acts on E. coli K12, B. subtilis W23 and P. fluorescens Pf-5 with the MIC50 values of 7 µg/mL, 12 µg/mL, and 46 µg/mL, respectively.
    MraY-IN-3
  • HY-15136B
    (Rac)-Lonafarnib 193275-86-4 98%
    (Rac)-Lonafarnib (Sch66336 racemate) is the racemate of Lonafarnib. Lonafarnib is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.
    (Rac)-Lonafarnib
Cat. No. Product Name / Synonyms Application Reactivity